View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 8, 2018

Science 37 and UCB partner to improve clinical trial experience

Science 37 has signed a strategic collaboration with global biopharmaceutical company UCB to improve clinical trial experience by facilitating more patient-friendly, technology-enabled trials at home.

Science 37 has signed a strategic collaboration with global biopharmaceutical company UCB to improve clinical trial experience by facilitating more patient-friendly, technology-enabled trials at home.

Under the collaboration, Science 37’s cloud-based mobile research platform, Network Oriented Research Assistant (NORA) will be used to offer greater patient value to the people participating in the trials conducted by UCB.

The decentralised approach of NORA is expected to provide data that will be more representative of patients’ real-life experiences.

It further aims to reduce the duration of product development and allow the faster launch of certain treatments.

"We created Science 37 to uniquely combine telemedicine technology, decentralised physician networks, and in-house experienced clinical study staff."

Initially, the partnership will focus on the areas of neurology and immunology.

The partnership is also expected to enable a more integrated study design process where the patient-centric mindset will help early protocol development.

Science 37 co-founder and CEO Noah Craft said: “We created Science 37 to uniquely combine telemedicine technology, decentralised physician networks, and in-house experienced clinical study staff to take on new and exciting research studies.”

The NORA platform is designed to allow end-to-end remote clinical trials and complies with the advanced industry quality and regulatory standards.

Science 37 has also developed the Metasite or ‘site-less’ model, which is designed to help researchers engage directly with trial participants through every stage of planning starting from screening and recruitment to data lock.

The model’s direct online connection enables greater retention of patients, increased diversity across trials, and faster recruitment.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU